<DOC>
	<DOCNO>NCT00072358</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , monoclonal antibody 3F8 , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Colony-stimulating factor , sargramostim , may increase number immune cell find bone marrow peripheral blood . Combining monoclonal antibody 3F8 sargramostim may cause strong immune response kill tumor cell . PURPOSE : Phase II trial study effectiveness combine monoclonal antibody 3F8 sargramostim treat patient neuroblastoma .</brief_summary>
	<brief_title>Monoclonal Antibody 3F8 Sargramostim Treating Patients With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy sargramostim ( GM-CSF ) enhance monoclonal antibody 3F8-mediated ablation patient high-risk neuroblastoma . - Determine prognostic impact minimal residual bone marrow disease relapse-free survival patient treat regimen . - Compare effect short-term ( 2-hour intravenous ) v prolong ( subcutaneous release ) daily GM-CSF granulocyte activation , order establish optimal route tumor-cell kill patient . OUTLINE : This open-label study . Patients stratify accord evaluable disease ( yes [ primary refractory bone marrow disease ] v [ evidence disease ] ) . Patients receive sargramostim ( GM-CSF ) subcutaneously day -5 4 monoclonal antibody 3F8 IV 0.5-1.5 hour day 0-4 . Treatment repeat every 3 week 4 course every 8 week total 24 month absence disease progression unacceptable toxicity . Beginning 2 course GM-CSF monoclonal antibody 3F8 , patient also receive oral isotretinoin twice daily day 1-14 ( monoclonal antibody 3F8 administer ) . Treatment isotretinoin repeat approximately every 28 day 6 course . PROJECTED ACCRUAL : A total 340 patient accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis neuroblastoma histopathology OR bone marrow metastases high urine catecholamine level Disease must meet riskrelated treatment guideline follow International Neuroblastoma Staging System stag : Stage 4 ( age ) OR without ( &gt; 18 month age age ) MYCN amplification MYCNamplified stage 1 No evidence disease ( i.e. , complete response/remission good partial response/remission ) OR disease resistant standard therapy ( i.e. , incomplete response bone marrow ) No progressive disease MIBGavid soft tissue tumor PATIENT CHARACTERISTICS : No exist renal , cardiac , hepatic , neurologic , pulmonary , gastrointestinal toxicity â‰¥ grade 3 No human antimouse antibody ( HAMA ) titer great 1,000 Elisa units/mL No history allergy mouse proteins No active lifethreatening infection Not pregnant Negative pregnancy test PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
</DOC>